Using nanoparticles that mimic VEGF to treat Spinocerebellar Ataxia Type 1

Who could benefit from this research

What this research studies

This research focuses on Spinocerebellar Ataxia Type 1 (SCA1), a progressive neurodegenerative disease. The team has discovered that a protein called ATXN1 affects levels of VEGF, a crucial factor for brain health, which are found to be low in SCA1. They aim to create nanoparticles that mimic VEGF to improve its delivery to brain cells, potentially enhancing neurovascular health. This innovative approach seeks to develop a new therapy that could significantly impact the treatment of SCA1.

Why it matters

Where this research is happening

• Northwestern University at Chicago
  Chicago, United States Active

Researchers

• Principal investigator: Opal, Puneet — Northwestern University at Chicago
• Study coordinator: Opal, Puneet

Related research

Other NIH-funded projects on the same topics.

• Modeling Ataxia Telangiectasia in a human stem cell model of Purkinje cells

  Researchers are creating a patient-derived, human cell model of Purkinje cells to understand why this brain disease causes cerebellar degeneration in people with Ataxia Telangiectasia.

  NIH research Rockefeller University · New York, United States · NIH-11605226

• VEGF-mimetic nanoparticles to help spinocerebellar ataxia type 1

  A new, patient-friendly approach is being developed to deliver a VEGF-like therapy using tiny particles that could protect brain cells in spinocerebellar ataxia type 1.

  NIH research Northwestern University · Chicago, United States · NIH-11565549

• Understanding early Friedreich ataxia in children to improve how we measure outcomes

  This study looks at how Friedreich ataxia starts and progresses in kids to create better, child-friendly measures for tracking the disease and testing treatments.

  NIH research Children's Hosp of Philadelphia · Philadelphia, United States · NIH-11494983

• Targeting FICD to Help Spinocerebellar Ataxia Type 3 (SCA3)

  A brain-focused project tests whether blocking FICD, a protein in cells’ ER quality system, can slow or prevent damage in people (via animal and cell studies) who have spinocerebellar ataxia type 3.

  NIH research University of Michigan at Ann Arbor · Ann Arbor, United States · NIH-11437540

• Understanding how unstable GAA repeats affect Friedreich’s ataxia progression

  A study in adults and children with Friedreich’s ataxia will look at how changes in GAA repeat length inside the FXN gene relate to the disease’s start and progression.

  NIH research Ut Southwestern Medical Center · Dallas, United States · NIH-11432740

• Biomarkers to measure how well QTE therapy works for Friedreich's ataxia

  Aiming to find blood and muscle signals that show whether a new FRDA treatment (QTE therapy) is working.

  NIH research Anekabio LLC · Gainesville, United States · NIH-11420527

About this research

1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.